High mobility group protein B1 is a predictor of poor survival in ovarian cancer

Lee Machado, Paul M Moseley, Robert Moss, Suha Deen, Christopher Nolan, Ian Spendlove, Judith Ramage

Research output: Contribution to journalArticleResearchpeer-review

Abstract

High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1. Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006). The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.
Original languageEnglish
JournalOncotarget
Volume8
Issue number60
DOIs
Publication statusPublished - 24 Nov 2017

Fingerprint

High Mobility Group Proteins
Ovarian Neoplasms
Survival
Neoplasms
Kaplan-Meier Estimate
Disease-Free Survival
Cell Survival
Immunohistochemistry
Monoclonal Antibodies
Databases

Keywords

  • DAMP
  • HMGB1
  • autophagy
  • ovarian cancer
  • prognostic

Cite this

Machado, Lee ; Moseley, Paul M ; Moss, Robert ; Deen, Suha ; Nolan, Christopher ; Spendlove, Ian ; Ramage, Judith. / High mobility group protein B1 is a predictor of poor survival in ovarian cancer. In: Oncotarget. 2017 ; Vol. 8, No. 60.
@article{5776349fca0941329b618d32b2875fc8,
title = "High mobility group protein B1 is a predictor of poor survival in ovarian cancer",
abstract = "High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1. Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006). The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.",
keywords = "DAMP, HMGB1, autophagy, ovarian cancer, prognostic",
author = "Lee Machado and Moseley, {Paul M} and Robert Moss and Suha Deen and Christopher Nolan and Ian Spendlove and Judith Ramage",
year = "2017",
month = "11",
day = "24",
doi = "10.18632/oncotarget.20538",
language = "English",
volume = "8",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "60",

}

High mobility group protein B1 is a predictor of poor survival in ovarian cancer. / Machado, Lee; Moseley, Paul M; Moss, Robert; Deen, Suha; Nolan, Christopher; Spendlove, Ian; Ramage, Judith.

In: Oncotarget, Vol. 8, No. 60, 24.11.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - High mobility group protein B1 is a predictor of poor survival in ovarian cancer

AU - Machado, Lee

AU - Moseley, Paul M

AU - Moss, Robert

AU - Deen, Suha

AU - Nolan, Christopher

AU - Spendlove, Ian

AU - Ramage, Judith

PY - 2017/11/24

Y1 - 2017/11/24

N2 - High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1. Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006). The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.

AB - High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1. Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006). The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.

KW - DAMP

KW - HMGB1

KW - autophagy

KW - ovarian cancer

KW - prognostic

UR - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=index

U2 - 10.18632/oncotarget.20538

DO - 10.18632/oncotarget.20538

M3 - Article

VL - 8

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 60

ER -